Vaios Hatzoglou1, T Jonathan Yang1, Antonio Omuro1, Igor Gavrilovic1, Gary Ulaner1, Jennifer Rubel1, Taylor Schneider1, Kaitlin M Woo1, Zhigang Zhang1, Kyung K Peck1, Kathryn Beal1, Robert J Young1. 1. Department of Radiology, Neuroradiology Service, Memorial Sloan Kettering Cancer Center, New York, New York (V.H., J.R., T.S., K.K.P., R.J.Y.); Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (T.J.Y., K.B.); Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York (G.U.); Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (A.O., I.G.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (K.M.W., Z.Z.); Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York (K.K.P.); Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York (V.H., A.O., I.G., K.B., R.J.Y.).
Abstract
BACKGROUND: The aim of this study was to assess the effectiveness of fluorine-18 fluorodeoxyglucose (FDG) PET-CT and dynamic contrast-enhanced (DCE) MRI in differentiating tumor progression and radiation injury in patients with indeterminate enhancing lesions after radiation therapy (RT) for brain malignancies. METHODS: Patients with indeterminate enhancing brain lesions on conventional MRI after RT underwent brain DCE-MRI and PET-CT in a prospective trial. Informed consent was obtained. Lesion outcomes were determined by histopathology and/or clinical and imaging follow-up. Metrics obtained included plasma volume (Vp) and volume transfer coefficient (K(trans)) from DCE-MRI, and maximum standardized uptake value (SUVmax) from PET-CT; lesion-to-normal brain ratios of all metrics were calculated. The Wilcoxon rank sum test and receiver operating characteristic analysis were performed. RESULTS: The study included 53 patients (29 treated for 29 gliomas and 24 treated for 26 brain metastases). Progression was determined in 38/55 (69%) indeterminate lesions and radiation injury in 17 (31%). Vpratio (VP lesion/VP normal brain, P < .001), K(trans) ratio (P = .002), and SUVratio (P = .002) correlated significantly with diagnosis of progression versus radiation injury. Progressing lesions exhibited higher values of all 3 metrics compared with radiation injury. Vpratio had the highest accuracy in determining progression (area under the curve = 0.87), with 92% sensitivity and 77% specificity using the optimal, retrospectively determined threshold of 2.1. When Vpratio was combined with K(trans) ratio (optimal threshold 3.6), accuracy increased to 94%. CONCLUSIONS: Vpratio was the most effective metric for distinguishing progression from radiation injury. Adding K(trans) ratio to Vpratio further improved accuracy. DCE-MRI is an effective imaging technique for evaluating nonspecific enhancing intracranial lesions after RT.
BACKGROUND: The aim of this study was to assess the effectiveness of fluorine-18 fluorodeoxyglucose (FDG) PET-CT and dynamic contrast-enhanced (DCE) MRI in differentiating tumor progression and radiation injury in patients with indeterminate enhancing lesions after radiation therapy (RT) for brain malignancies. METHODS:Patients with indeterminate enhancing brain lesions on conventional MRI after RT underwent brain DCE-MRI and PET-CT in a prospective trial. Informed consent was obtained. Lesion outcomes were determined by histopathology and/or clinical and imaging follow-up. Metrics obtained included plasma volume (Vp) and volume transfer coefficient (K(trans)) from DCE-MRI, and maximum standardized uptake value (SUVmax) from PET-CT; lesion-to-normal brain ratios of all metrics were calculated. The Wilcoxon rank sum test and receiver operating characteristic analysis were performed. RESULTS: The study included 53 patients (29 treated for 29 gliomas and 24 treated for 26 brain metastases). Progression was determined in 38/55 (69%) indeterminate lesions and radiation injury in 17 (31%). Vpratio (VP lesion/VP normal brain, P < .001), K(trans) ratio (P = .002), and SUVratio (P = .002) correlated significantly with diagnosis of progression versus radiation injury. Progressing lesions exhibited higher values of all 3 metrics compared with radiation injury. Vpratio had the highest accuracy in determining progression (area under the curve = 0.87), with 92% sensitivity and 77% specificity using the optimal, retrospectively determined threshold of 2.1. When Vpratio was combined with K(trans) ratio (optimal threshold 3.6), accuracy increased to 94%. CONCLUSIONS: Vpratio was the most effective metric for distinguishing progression from radiation injury. Adding K(trans) ratio to Vpratio further improved accuracy. DCE-MRI is an effective imaging technique for evaluating nonspecific enhancing intracranial lesions after RT.
Authors: R K Gupta; R Awasthi; R K Garg; N Kumar; P K Gupta; A K Singh; P Sahoo; V K Paliwal; K N Prasad; C M Pandey; R K S Rathore Journal: AJNR Am J Neuroradiol Date: 2012-11-22 Impact factor: 3.825
Authors: Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: Vaios Hatzoglou; Gary A Ulaner; Zhigang Zhang; Kathryn Beal; Andrei I Holodny; Robert J Young Journal: Clin Imaging Date: 2012-10-12 Impact factor: 1.605
Authors: Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu Journal: Neurosurgery Date: 2019-08-01 Impact factor: 4.654
Authors: A D Schweitzer; G C Chiang; J Ivanidze; H Baradaran; R J Young; R D Zimmerman Journal: AJNR Am J Neuroradiol Date: 2016-12-01 Impact factor: 3.825
Authors: Francesco Cicone; Norbert Galldiks; Giuseppe Minniti; Christian P Filss; Francesco Scopinaro; John O Prior; Nathalie L Albert; Karl-Josef Langen Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: J I Traylor; D C A Bastos; D Fuentes; M Muir; R Patel; V A Kumar; R J Stafford; G Rao; S S Prabhu Journal: AJNR Am J Neuroradiol Date: 2019-08-01 Impact factor: 3.825